Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Land & Improvements (2016 - 2019)

Myriad Genetics has reported Land & Improvements over the past 5 years, most recently at $2.2 million for Q3 2019.

  • Quarterly Land & Improvements fell 8.33% to $2.2 million in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Sep 2019, down 8.33% year-over-year, with the annual reading at $2.3 million for FY2019, 4.17% down from the prior year.
  • Land & Improvements was $2.2 million for Q3 2019 at Myriad Genetics, down from $2.3 million in the prior quarter.
  • Over five years, Land & Improvements peaked at $2.5 million in Q4 2017 and troughed at $2.2 million in Q4 2016.
  • The 5-year median for Land & Improvements is $2.3 million (2015), against an average of $2.3 million.
  • Year-over-year, Land & Improvements grew 13.64% in 2017 and then dropped 8.33% in 2019.
  • A 5-year view of Land & Improvements shows it stood at $2.3 million in 2015, then decreased by 4.35% to $2.2 million in 2016, then grew by 13.64% to $2.5 million in 2017, then decreased by 4.0% to $2.4 million in 2018, then decreased by 8.33% to $2.2 million in 2019.
  • Per Business Quant, the three most recent readings for MYGN's Land & Improvements are $2.2 million (Q3 2019), $2.3 million (Q2 2019), and $2.3 million (Q1 2019).